CERO Company Profile and Key Details

NASDAQ : CERO

CERo Therapeutics

$0.03

-0.0009-2.65%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

CERo Therapeutics Holdings, Inc. (CERO) stock declined over -2.65%, trading at $0.03 on OTC, down from the previous close of $0.03. The stock opened at $0.03, fluctuating between $0.03 and $0.04 in the recent session.

Stock Snapshot

0.034

Prev. Close

39.9K

Market Cap

0.033

Day Low

-0.01

P/E Ratio

-2.32

EPS (TTM)

N/A

Cash Flow per Share

0.03

Open

1.21M

Number of Shares

0.0399

Day High

91.49%

Free Float in %

N/A

Book Value

243.02K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 25, 2026	0.04	0.04	0.03	0.03	368K
Mar 24, 2026	0.04	0.04	0.03	0.03	580.81K
Mar 23, 2026	0.04	0.04	0.04	0.04	32.43K
Mar 20, 2026	0.04	0.04	0.03	0.03	211.59K
Mar 19, 2026	0.04	0.04	0.03	0.04	206.73K
Mar 18, 2026	0.03	0.04	0.03	0.03	109.31K
Mar 17, 2026	0.04	0.04	0.03	0.03	52.35K
Mar 16, 2026	0.04	0.04	0.03	0.03	96.28K
Mar 13, 2026	0.04	0.04	0.03	0.03	427.34K
Mar 12, 2026	0.03	0.04	0.03	0.03	982.2K
Mar 11, 2026	0.04	0.04	0.03	0.03	310.21K
Mar 10, 2026	0.04	0.04	0.03	0.03	213.58K
Mar 09, 2026	0.03	0.04	0.03	0.03	220.49K
Mar 06, 2026	0.04	0.04	0.03	0.03	681.02K
Mar 03, 2026	0.04	0.04	0.03	0.04	241.76K
Mar 02, 2026	0.03	0.04	0.03	0.03	264.98K
Feb 27, 2026	0.04	0.04	0.04	0.04	1.85M
Feb 26, 2026	0.04	0.04	0.04	0.04	787.31K
Feb 25, 2026	0.04	0.04	0.04	0.04	363.38K
Feb 24, 2026	0.04	0.04	0.04	0.04	214.79K

Contact Details

South San Francisco, CA 94080

United States

https://www.cero.bio 650 407 2376

About Company

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Stock Peers

ODTC

Odonate Therapeutics, Inc.$2,849.50 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 NONOF

Novo Nordisk A/S$144.95 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 NURPF

Neuren Pharmaceuticals Limited$14.00 TLPPF

Telix Pharmaceuticals Limited$11.00

Company Overview

The stock is currently trading near its 52-week low $0.03 and $28.40. With a market capitalization of about $39.90 thousand, CERo Therapeutics Holdings, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.32). Key stats such as the average daily volume over the past year has been around 519.89 thousand shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, CERo Therapeutics Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Christopher Ehrlich, the company employs approximately 8 people and listed since November 30, 2021. CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.

Technical Performance

CERO has shown weak momentum, losing -95.24% over the past week and -98.76% over the past quarter, though year-to-date performance is down -99.92%. Short-term trend indicators are bullishly aligned (SMA20 -96.73%, SMA50 -98.04%, SMA200 -99.37%). The stock’s 14-day RSI is 12.27 (weak momentum), while the ATR of 0.44 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.99% below its high and over 11.88% above its low. Average 10-day trading volume of 207.19 thousand shares is below the 3-month average of 516.99 thousand, indicating normal recent market interest.

Valuation Metrics

CERo Therapeutics Holdings, Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.04 and a price-to-book ratio of -0.01 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.01, also above market averages.

Dividend & Fair Value

CERo Therapeutics Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.45. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $30.00. The high target offers 99900.0% upside. The low target suggests 99900.0% downside. The mean target is $30.00. This offers 99900.0% upside. CERo Therapeutics Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended November 19, 2025, missed forecasts by 1097.37%. The prior quarter beat by -50.34%. Over the last six quarters, Apple has recorded several small beats. These include -73.32% in May 15, 2025.

Shareholding & Insider Activity

CERo Therapeutics Holdings, Inc. has 1.21 million shares outstanding. The public float is 1.10 million shares, elevated short interest at 3.23% of float. This equals 38.01 thousand shares. The short ratio is 1.0 days. Institutional investors hold 26.68% of the float. Insiders own 3.55%.

Financial & Profitability Overview

Over the trailing twelve months, CERo Therapeutics has not generated any revenue.
On valuation metrics, CERo Therapeutics trades at a P/E of -0.00, P/S of 0.04 and P/B of -0.01. Liquidity is tight, with a current ratio of 0.30 and quick ratio of 0.30. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1856.69 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -0.20, supported by a cash flow-to-debt ratio of -8.73.

Price Forecast & Outlook

Our AI price prediction model suggests that CERo Therapeutics Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.37%, with price expected at $0.03 by April 08, 2026, within a range of $0.03 to $0.03 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by June 22, 2026, with a range of $0.00 to $8.30. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by March 25, 2027, within a range of $0.00 to $128.99.

Key Takeaways

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) shares are down -99.92% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows CERo Therapeutics Holdings, Inc. trading at a premium to the broader market with a P/E of -0.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $30.00, suggesting 90534.44% upside. Our AI forecast model points to short-term weakness (-9.37% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current CERo Therapeutics Holdings, Inc. (CERO) stock price?

CERo Therapeutics Holdings, Inc. (OTC: CERO) stock price is $0.03 in the last trading session. During the trading session, CERO stock reached the peak price of $0.04 while $0.03 was the lowest point it dropped to. The percentage change in CERO stock occurred in the recent session was -2.65% while the dollar amount for the price change in CERO stock was - $0.00.

CERO's industry and sector of operation?

The OTC listed CERO is part of Biotechnology industry that operates in the broader Healthcare sector. CERo Therapeutics Holdings, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CERO?

No Data

How CERO did perform over past 52-week?

CERO's closing price is 0.3% higher than its 52-week low of $0.03 where as its distance from 52-week high of $28.40 is -99.88%.

How many employees does CERO have?

Number of CERO employees currently stands at 8.

Link for CERO official website?

Official Website of CERO is: https://www.cero.bio

How do I contact CERO?

CERO could be contacted at phone 650 407 2376 and can also be accessed through its website. CERO operates from 201 Haskins Way, South San Francisco, CA 94080, United States.

How many shares of CERO are traded daily?

CERO stock volume for the day was 243.02K shares. The average number of CERO shares traded daily for last 3 months was 519.89K.

What is the market cap of CERO currently?

The market value of CERO currently stands at $39.90K with its latest stock price at $0.03 and 1.21M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	8
Beta	0.32
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

CERO Company Profile and Key Details

CERo Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Dividend & Fair Value

Valuation Metrics

Key Takeaways

Price Forecast & Outlook